Other Events ·
Incannex Healthcare Inc. received a final A$5,102,788.30 refund under the Australian Government’s Research and…
IXHLIncannex Healthcare Inc.
Incannex Healthcare Inc. received a final A$5,102,788.30 refund under the Australian Government’s Research and Development Tax Incentive Program on August 11, 2026. This payment completes more than A$11.2 million in non-dilutive capital received during 2026, following a previous refund of A$6,039,162.43. The funds result from the approval of overseas findings and an amended FY25 income tax return. This receipt strengthens the company's debt-free balance sheet and financial flexibility to advance its clinical pipeline without shareholder dilution. Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and psychedelic-assisted treatments for conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.